The European Commission has fined Danish pharmaceutical firm Lundbeck €93.8 million, saying it paid rival companies to delay production of generic versions of anti-depressant medication Citalopram.
It is the first "pay for delay" case brought by the EU.
The EU's executive arm focused on 2002, when patent protection for the molecule used to make Citalopram lapsed and rival pharmaceutical firms were able to produce generic versions of its drug.
Lundbeck - the so-called "orig...
Enjoy access to all articles and 25 years of archives, comment and gift articles. Become a member for as low as €1,75 per week.
Already a member? LoginBenjamin Fox is a seasoned reporter and editor, previously working for fellow Brussels publication Euractiv. His reporting has also been published in the Guardian, the East African, Euractiv, Private Eye and Africa Confidential, among others. He heads up the AU-EU section at EUobserver, based in Nairobi, Kenya.
Benjamin Fox is a seasoned reporter and editor, previously working for fellow Brussels publication Euractiv. His reporting has also been published in the Guardian, the East African, Euractiv, Private Eye and Africa Confidential, among others. He heads up the AU-EU section at EUobserver, based in Nairobi, Kenya.